PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Clinical trial NCT00332202 · COMPLETED

Trial details

NCT number: NCT00332202
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Non Hodgkin Lymphoma

Start date: 2006-06-01
Primary completion: 2013-04-01
Enrollment: 758

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.